ClinicalTrials.gg
RecruitingNCT01950624Updated Jan 31, 2025

DS-Connect®: The Down Syndrome Registry

An observational study in Down Syndrome, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by University of Colorado, Denver · Observational

How we know

From the registry’s dates

  • Started Sep 2013; still recruiting 13 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Down Syndrome by University of Colorado, Denver — 4 open to participants now, 4 under way, 1 of them phase 3. Down Syndrome · University of Colorado, Denver.

Started
2013
the only one that year
Observational
5 of 12
2 open now
Registered
2nd of 12
by date

Among the 12 studies in Down Syndrome by University of Colorado, Denver, this one is the only one that started in 2013, is one of 5 observational ones, and was the 2nd registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

4 of the 12 studies in Down Syndrome by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Down Syndrome by University of Colorado, Denver, or all of them as a file.
02

Study summary

The goal of this study is to develop a registry for Down syndrome (DS) to facilitate research participation by individuals with Down syndrome.

DS-Connect® is an online survey tool designed to collect demographic data and health information from individuals with DS. It is open to all people with Down syndrome.

The purposes of DS-Connect® are:

  1. To identify the various phenotypic manifestations of DS.
  2. To identify individuals with DS who may be eligible for research studies or new clinical trials, based on specific information about their diagnosis and health history.
Read the detailed description

The DS-Connect® Registry is a unique resource that enables communication and sharing of ideas among the NIH, individuals with DS and their families, national and international organizations interested in DS, and a diverse group of professionals involved in scientific research and medical care benefiting the population with DS. By providing information on their demographics, health histories, medications, and other relevant biomedical information, self-advocates and their families provide an unprecedented view of this genetic condition that can inspire new scientific inquiries, clinical research, and clinical trials specifically serving this population. For example, the DS-Connect® dataset has led to an increasing appreciation of the prevalence of many co-occurring conditions affecting individuals with DS across the lifespan, thus providing the rationale for the launch of the NIH INCLUDE Project (INvestigation of Co-occurring conditions across the Lifespan to Understand Down SyndromE). Conversely, self-advocates and their families participating in DS-Connect® benefit in several ways, including valuable comparison of their health histories with metrics from the entire cohort, access to key resources (e.g., list of active clinical trials), as well as opportunities for participation in human research protocols, including clinical trials testing new interventions to address diverse aspects of this condition. In turn, the DS-Connect® dataset informs both NIH and the research community on the need to support specific research areas, while also providing an avenue for researchers to promote recruitment into their studies. Altogether, DS-Connect® provides a multimodal platform for exchange of information and ideas across all key stakeholders, assuring that scientific research in this field is attuned to the needs of the community.

A person with DS or a family member or caregiver can register directly through the DS-Connect® website at their convenience. They may learn of the Registry from many sources including partner advocacy groups, government and healthcare organizations, or other families who are members in the Registry. The DS-Connect® platform readily captures participant information using condition-specific surveys.

All information is provided by the participant or representative for the participant via the web-based Registry. There are no in-person visits required for registration.

03

Conditions studied

  • Down Syndrome

Browse trials for

Keywords

  • Patient Registry
  • Down Syndrome
  • Natural History
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with DS (including those with mosaic DS and partial trisomy 21).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (at least 18 years of age) with a diagnosis of DS (including mosaic DS or partial trisomy 21) who are capable of providing consent to participate, or for whom a legally authorized representative (LAR) may give permission on behalf of the individual to participate. Adults with DS who cannot consent for themselves but can provide assent would need to provide assent to their LAR.
  • Children (up to age 18 years of age) with a diagnosis of DS. Parents/guardians may enter registry information and give permission to participate on behalf of their child; if the child is over 7 years of age and able to provide assent, they must do so. (Note: Once a child has reached age 18, he or she will be prompted to re-enroll into the registry as an adult, if he/she is able to provide or with the consent of his/her LAR if unable to re-enroll themselves.)

No individuals with DS will be excluded from taking part in DS-Connect based on age, race, ethnicity, or gender.

Exclusion criteria

EXCLUSION CRITERIA:

  • A person who does not have a diagnosis of DS (or mosaic DS or partial trisomy 21)
  • Adults with DS who are not capable of providing or assent to participate and do not have a Legally Authorized Representative who can do so. In the case where an adults with DS is able to provide assent but does not do so, that adult will be excluded.
  • A participant, parent, and/or LAR who cannot provide consent or does not read or understand a language that is available for the registry, either English or Spanish.
  • A child with DS (between the ages of 7 and 18 years) who is capable of providing assent but does not do so.
  • A child under the age of 18 years whose parents share joint custody and one parent indicates that they do not consent to the child's participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Down syndrome cohort

    Individuals who have a diagnosis of complete trisomy 21, translocation Down syndrome or mosaic Down syndrome.

06

What researchers measure

Primary outcomes

  1. To determine the prevalence of the various co-occurring conditions in Down syndrome.

    Participants in DS-Connect® will complete health history surveys regarding medical diagnoses and can update the surveys annually or whenever their health changes.

    Time frame: Through study completion, up to 10 years

  2. Facilitate participation in research for individuals with DS who may be eligible for research studies or new clinical trials.

    Participants may choose to hear about Down syndrome research studies that may be relevant to their co-occurring conditions.

    Time frame: Through study completion, up to 10 years

Secondary outcomes

  1. Enable aggregate data sharing from individuals with Down syndrome.

    Consented individuals will have their de-identified data shared with the INCLUDE Data Hub to enable researchers to understand etiology, natural history, and/or treatment effectiveness in Down syndrome.

    Time frame: Through study completion, up to 10 years

07

Study locations

1 of 1 sites recruiting
  • Linda Crnic Institute for Down Syndrome
    Aurora, Colorado 80045, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be available to other researchers through the INCLUDE Data Hub.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2013 (actual). Primary completion is estimated for Jun 2035, 261 months after the start.

Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 261 months is above that.

Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2013
First posted
Sep 25, 2013
StartActual
Sep 6, 2013
Primary completionEst.
Jun 2035
CompletionEst.
Jun 2035
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01950624
Responsible party
Sponsor
First posted
Sep 25, 2013
Start date
Sep 6, 2013
Primary completion
Jun 2035 (estimated)
Completion
Jun 2035 (estimated)
Last update
Jan 31, 2025

Study contacts

Anne Fiala
Contact
info@ds-connect.org
(303) 724-6599
Angela Rachubinski, PhD
Contact
Joaquin M Espinosa, Ph.D.
principal investigator · Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion